指南与共识男科与性医学

欧洲泌尿外科学会-美国临床肿瘤学会阴茎癌协作指南:2023年更新

European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update.
指南 / 共识 · Eur Urol · 2023-03-10

该协作指南针对罕见但全球发病率上升的阴茎癌,通过综合文献检索及三项系统综述,采用GRADE方法评估证据并给出推荐。指南强调HPV是主要风险因素、原发肿瘤治疗需平衡根治与器官保留、淋巴结转移的早期诊治是生存关键,并推荐高危(≥pT1b)cN0患者行前哨淋巴结活检。

要点

  • HPV是阴茎癌主要风险因素,病理评估应包括HPV状态检测。
  • 原发肿瘤治疗目标是完全根除肿瘤,需平衡器官保留与肿瘤学控制。
  • 高危(≥pT1b)cN0患者推荐行前哨淋巴结活检进行手术分期。

核心结论

  • 该协作指南提供了阴茎癌诊断和治疗的最新信息以供临床实践使用。
  • 原发肿瘤治疗在可行时应提供器官保留手术。
  • 充分且及时的淋巴结管理仍是一项挑战,尤其是在晚期疾病阶段。
  • 推荐将患者转诊至专家中心。

研究设计与样本

  • 由欧洲泌尿外科学会(EAU)与美国临床肿瘤学会(ASCO)协作制定。
  • 针对各章节主题进行了全面文献检索,并开展了三项系统综述。
  • 采用GRADE方法评估证据水平并为每条推荐赋予强度评级。

主要发现

  • 阴茎癌是一种罕见疾病,但其全球发病率正在上升。
  • 人乳头瘤病毒(HPV)是阴茎癌的主要风险因素,病理评估应包括HPV状态检测。
  • 原发肿瘤治疗的主要目标是完全根除肿瘤,须在不影响肿瘤学控制的前提下与最佳器官保留相平衡。
  • 淋巴结转移的早期发现和治疗是生存的主要决定因素。
  • 由于缺乏对照试验和大系列研究,与更常见疾病相比,证据水平和推荐等级较低。

关键数值与推荐

  • 推荐对高危(≥pT1b)肿瘤且cN0状态的患者行前哨淋巴结活检进行手术淋巴结分期。
  • 腹股沟淋巴结清扫仍是淋巴结阳性疾病的标准治疗。
  • 晚期疾病患者需要多模式治疗。
  • 可行时应提供器官保留手术治疗原发肿瘤。
  • 推荐转诊至专家中心。

临床怎么用

  • 病理评估应包括HPV状态检测。
  • 高危(≥pT1b)cN0患者推荐行前哨淋巴结活检进行手术分期。
  • 淋巴结阳性疾病以腹股沟淋巴结清扫为标准。
  • 晚期疾病患者需要多模式治疗。
  • 推荐将患者转诊至专家中心。

局限性

  • 由于缺乏对照试验和大系列研究,与更常见疾病相比,证据水平和推荐等级较低。
  • 晚期疾病阶段的淋巴结管理仍是一项挑战。
  • 许多未满足的需求和未解答的问题仍然存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Penile cancer is a rare disease but has a significant impact on quality of life. Its incidence is increasing, so it is important to include new and relevant evidence in clinical practice guidelines. OBJECTIVE: To provide a collaborative guideline that offers worldwide physician and patient guidance for the management of penile cancer. EVIDENCE ACQUISITION: Comprehensive literature searches were performed for each section topic. In addition, three systematic reviews were conducted. Levels of evidence were assessed, and a strength rating for each recommendation was assigned according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) methodology. EVIDENCE SYNTHESIS: Penile cancer is a rare disease but its global incidence is increasing. Human papillomavirus (HPV) is the main risk factor for penile cancer and pathology should include an assessment of HPV status. The main aim of primary tumour treatment is complete tumour eradication, which has to be balanced against optimal organ preservation without compromising oncological control. Early detection and treatment of lymph node (LN) metastasis is the main determinant of survival. Surgical LN staging with sentinel node biopsy is recommended for patients with a high-risk (≥pT1b) tumour with cN0 status. While (inguinal) LN dissection remains the standard for node-positive disease, multimodal treatment is needed in patients with advanced disease. Owing to a lack of controlled trials and large series, the levels of evidence and grades of recommendation are low in comparison to those for more common diseases. CONCLUSIONS: This collaborative penile cancer guideline provides updated information on the diagnosis and treatment of penile cancer for use in clinical practice. Organ-preserving surgery should be offered for treatment of the primary tumour when feasible. Adequate and timely LN management remains a challenge, especially in advanced disease stages. Referral to centres of expertise is recommended. PATIENT SUMMARY: Penile cancer is a rare disease that significantly impacts quality of life. While the disease can be cured in most cases without lymph node involvement, management of advanced disease remains challenging. Many unmet needs and unanswered questions remain, underlining the importance of research collaborations and centralisation of penile cancer services.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Brouwer OR, Albersen M, Parnham A, et al. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol. 2023. PMID: 36906413. doi:10.1016/j.eururo.2023.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。